Melbourne, Victoria, Australia
Health Economist with a demonstrated history of developing evidence-based policy solutions to address complex public health issues and communicating findings to a wide range of audiences. I am skilled in health economic modelling, economic evaluation, health technology assessment (HTA) and policy analysis. My research interests are largely driven by a sense of social justice, aiming to improve health equity through addressing the socio-economic determinants of health (particularly during the formative adolescent years), and increasing access to effective therapies for those with unmet needs.
As a member of the NDIS Evidence Advisory Committee (EAC) Economics sub-committee, I will advise government, informed by the best available evidence about the benefits, quality, safety and cost-effectiveness of NDIS supports. This advice will improve participant outcomes and experiences and help improve the NDIS
As part of the Melbourne Value Assessment Collaboration (M-VAC) I undertake several activities including: -Supporting decisions about the listing of new medical devices and pharmaceuticals for State Governments, Medical Services Advisory Committee (MSAC), Pharmaceutical Benefits Advisory Committee (PBAC) -Post-market Review (e.g., MBS Review) -Prosthesis List Reform -HTA rapid reviews -Development-focused HTA: Early lifecycle advice, guidance, and value proposition development for early stage innovations, including technologies, services, system reforms, and digital health applications (e.g., via the Validitron) -National screening programs -Payment system reforms
As part of the Centre of Health Economics Research and Evaluation (CHERE) I am a member of the Health Technology Assessment (HTA) team, responsible for appraising submissions to the Pharmaceutical Benefits Advisory committee (PBAC). Additionally I am a member of the Cancer Research Economics Support Team (CREST), providing expert advice and support to the Multi-site Collaborative Cancer Clinical Trials Groups.